Summary
An open-label, randomized, multi-center study to evaluate the use of Study Drug in the prevention of cancer treatment-related bone loss in post-menopausal women with ER+ and/or PR+ breast cancer receiving letrozole as adjuvant therapy.
Register to download
Meeting Enrollment Goals Breast Cancer
You may also be interested in:
Fact Sheet
CSF Sampling
PRA understands how cerebrospinal fluid (CSF) sampling benefits our clients’ early phase trials. We regularly conduct CSF sampling to collect key PK…
View Resource
page
Wearables and Virtual Trials
At PRA, we’re elevating decentralized clinical trial design to work for patients in today’s modern world. By leveraging our data, expertise, and…
Read More
Case Study
PRA’s Unique Model Leads to Client Satisfaction
A randomized, multi-center, double-blind study to compare the efficacy and safety of Study Drug A and Study Drug B as monotherapy in newly diagnosed…
View Resource
View all related content and resources for Study Design
Explore Insights